References
- Baldwin DS. Room for improvement in the pharmacological treatment of anxiety disorders. Current Pharmaceutical Design 2008; 14: 4382–3491.
- Roy-Byrne P, Veitengruber JP, Bytritsky A, et al. Brief intervention for anxiety in primary care. J Am Board Fam Med 2009; 22(2): 175–86.
- Strine TW, Mokdad AH, Balluz LS, et al. Depression and anxiety in the United States: Findings from the 2006 behavioural risk factor surveillance system. Psychiatr Serv 2008; 59: 1383–90.
- Herman AA, Stein DJ, Seedat S, Heeringa SG, Moornal H, Williams DR. The South African stress and health (SASH) study: 12-month and lifetime prevalence of common mental disorders. SAMJ 2009; 99(5): 339–44.
- Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJG, Kubzansky L, Lydiard RB. Anxiety disorders and co-morbid medical illness. General Hospital Psychiatry 2008; 30: 208–25.
- Kessler D, Lloyd K, Lewis G, Gray DP. Cross sectional study of symptom attribution and recognition of depression and anxiety in primary care. BMJ 1999; 318: 436–90.
- Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: Prevalence, impairment, co-morbidity and detection. Ann Intern Med 2007; 146: 317–25.
- Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry 2004; 161: 2230–7.
- Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalised social anxiety disorder; Results of a double blind placebo controlled study. J Clin Psychiatry 2003; 64: 785–92.
- Bandelow B. Future perspectives: New compounds with putative anxiolytic effects. Program and abstracts of the International Congress of Biological Psychiatry; 2004; Sydney, Australia. Workshop 56.
- Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann N Y Acad Sci 2003; 985: 420–44.
- Whalen PJ, Shin LM, Somerville LH, McLean AA, Kim H. Functional neuroimaging studies of the amygdala in depression. Semin Clin Neuropsychiatry 2002; 7: 234–42.
- Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005; 10(1): 49–56.
- Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP task force. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 2008; 9(4): 248–312.
- Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19(6): 567–96.
- Garner M, Mohler H, Stein DJ, Mueggler T, Baldwin DS. Research in anxiety disorders: From the bench to the bedside. Eur Neuropsychopharmacol 2009; 19: 381–90.
- Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalised anxiety disorder: The GAD-7. Arch Intern Med 2006; 166: 1092–7.
- Norman SB, Cissell SH, Means-Christensen AJ. Development and validation of an overall anxiety severity and impairment scale (OASIS). Depres Anxiety 2006; 23: 245–9.
- Stein DJ, Ahokas A, Fabiano A. Agomelatine in generalised anxiety disorder: A randomised placebo controlled study. Eur Neuropsychopharmacol 2007; 17(4): S509–S510.